{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T04:18:34Z","timestamp":1697343514104},"reference-count":27,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:00:00Z","timestamp":1340841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> A semiautomated method of component production from whole blood was implemented at Canadian Blood Services. To assess safety of the new components, the frequency of adverse transfusion events (ATEs) to platelet components (PCs) and red blood cell (RBCs) produced before and after implementation of the new method was surveyed and compared.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> This retrospective, observational, noninferiority study was conducted in 12 sentinel hospitals across Canada. The control group received RBCs in additive solution\u20103 (AS\u20103) and platelet\u2010rich plasma (PRP)\u2010produced platelets (PLTs) for 3 to 11 months before implementation of semiautomated production, and the study group received RBCs in saline\u2010adenine\u2010glucose\u2010mannitol (SAGM) and buffy coat (BC)\u2010produced PLTs for 3 to 11 months after implementation. ATE definitions at each hospital and standard practice for reporting did not change between control and study periods. Data for analysis were obtained from databases and original report forms.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> The pooled risk ratio of a reaction to SAGM versus AS\u20103 RBCs was 0.77 (95% confidence interval [CI], 0.66\u20100.90), suggesting that SAGM products had significantly lower reaction rates than AS\u20103 products (p\u2003&lt;\u20030.01). Reported allergic reactions to RBCs decreased from 0.07% (AS\u20103) to 0.04% (SAGM). For PLTs, the difference in reaction rates between BC and PRP was not significant (p\u2003=\u20030.37), and the pooled risk ratio of BC versus PRP was 1.14 (95% CI, 0.86\u20101.50).<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> The change in manufacturing method was associated with lower reaction rates to SAGM RBCs than to AS\u20103 RBCs. Pooled BC PLTs were noninferior to random\u2010donor PRP PLTs with respect to ATEs.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2012.03752.x","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T04:41:15Z","timestamp":1340858475000},"page":"2683-2691","source":"Crossref","is-referenced-by-count":15,"title":["Transfusion reactions: a comparative observational study of blood components produced before and after implementation of semiautomated production from whole blood"],"prefix":"10.1111","volume":"52","author":[{"given":"Elisabeth","family":"Semple","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Bowes\u2010Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi\u2010Long","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Shimla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana V.","family":"Devine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,6,28]]},"reference":[{"key":"e_1_2_8_2_2","volume-title":"AABB technical manual","author":"Roback JD","year":"2011"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2005.00559.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03330.x"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.15.1941"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1993.tb02124.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1993.331094054613.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1994.tb01273.x"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0041-1132.2003.00518.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.1997.d01-73.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1996.361097017174.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01836.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02441.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02555.x"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-2824.2010.01366.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2011.11.001"},{"key":"e_1_2_8_17_2","unstructured":"Canadian Blood Services.Customer Letter #2005\u201003 Buffy Coat Production Method. Ottawa ON Canada: Canadian Blood Services 2005. [cited 2012 May 4]. Available from: URL:http:\/\/blood.ca\/CentreApps\/Internet\/UW_V502_MainEngine.nsf\/resources\/Customer+Letters\/$file\/CL\u20102005\u201003\u2010%282005\u201005\u201026%29_ENG.pdf"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03187.x"},{"key":"e_1_2_8_19_2","unstructured":"Public Health Agency of Canada.Transfusion Transmitted Injuries Surveillance System\u2014User's Manual.2007. [cited 2011 Oct 27]. Available from: URL:http:\/\/www.phac\u2010aspc.gc.ca\/hcai\u2010iamss\/tti\u2010it\/pdf\/users_manual_07_e.pdf"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.moh.0000239703.40297.a5"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0041-1132.2005.04467.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03229.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.03008.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.03009.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409083311001"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2003.08.013"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2011.01556.x"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2011.01713.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2012.03752.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2012.03752.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T17:18:22Z","timestamp":1697303902000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2012.03752.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,28]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/j.1537-2995.2012.03752.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2012.03752.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,28]]}}}